Teladoc Health, Inc. (NYSE:TDOC) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Teladoc Health, Inc. (NYSE:TDOC) have been assigned an average rating of “Hold” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $19.67.

Several brokerages recently issued reports on TDOC. Barclays dropped their price objective on Teladoc Health from $25.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday. TD Cowen dropped their target price on Teladoc Health from $16.00 to $15.00 and set a “hold” rating on the stock in a research report on Friday. Royal Bank of Canada dropped their target price on Teladoc Health from $25.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday. Evercore ISI lowered their price objective on Teladoc Health from $15.00 to $14.00 and set an “in-line” rating for the company in a research report on Friday. Finally, SVB Leerink began coverage on Teladoc Health in a research report on Monday, February 26th. They issued a “market perform” rating and a $17.00 price objective for the company.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the completion of the transaction, the insider now owns 57,223 shares in the company, valued at approximately $1,097,537.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the completion of the transaction, the insider now owns 57,223 shares in the company, valued at approximately $1,097,537.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jason N. Gorevic sold 53,755 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $780,522.60. Following the sale, the chief executive officer now owns 653,073 shares in the company, valued at $9,482,619.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 135,441 shares of company stock worth $2,038,251. Insiders own 1.63% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

A number of institutional investors have recently modified their holdings of TDOC. Vanguard Group Inc. grew its position in shares of Teladoc Health by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after acquiring an additional 1,855,480 shares during the period. ARK Investment Management LLC boosted its holdings in Teladoc Health by 4.5% in the 4th quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock worth $457,389,000 after buying an additional 912,692 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Teladoc Health by 25.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock worth $82,636,000 after buying an additional 767,999 shares during the last quarter. Norges Bank acquired a new stake in Teladoc Health in the 4th quarter worth about $9,714,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Teladoc Health by 37.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,549,585 shares of the health services provider’s stock worth $28,807,000 after buying an additional 418,909 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Trading Down 2.4 %

Shares of NYSE TDOC opened at $13.01 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. The business’s 50 day moving average price is $15.01 and its 200-day moving average price is $17.77. Teladoc Health has a fifty-two week low of $12.65 and a fifty-two week high of $30.41. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -9.71 and a beta of 0.94.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The firm had revenue of $646.13 million during the quarter, compared to the consensus estimate of $637.31 million. During the same period last year, the company earned ($0.37) EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, sell-side analysts expect that Teladoc Health will post -1.07 earnings per share for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.